What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Oral administration of AMC6156 in tablet form at a dose of 0.1 mg once daily for 12 weeks.”In the company’s words, NCT07072195 on ClinicalTrials.gov
- Tested for
- Sarcopenia in Elderly, Sarcopenia
- Main trialPhase 2
- “This clinical trial aims to find out whether AMC6156 can improve physical function and is safe in older adults with sarcopenia. Participants will take AMC6156 or a placebo daily for 12 weeks, and their movement, strength, and safety will be regularly monitored through tests and checkups.”In the company’s words, NCT07072195 on ClinicalTrials.gov
Other drugs for Sarcopenia in Elderly
- PLH-2301Pluto Inc. · Phase 2
- TJ0113Hangzhou PhecdaMed Co., Ltd. · Phase 2
- MF-300Epirium Bio Inc. · Phase 2
- Bone marrow mesenchymal stem cellsGuangZhou Cellgenes Biotechnology Co., Ltd. · Phase 1/2
- BimagrumabEli Lilly · Phase 2
- EN001ENCell · Phase 1/2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 31 Oct 2026 | A Study of AMC6156 in People With Sarcopenia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026